177 related articles for article (PubMed ID: 36902104)
1. Imbalanced IL-1B and IL-18 Expression in Sézary Syndrome.
Manfrere KCG; Torrealba MP; Ferreira FM; de Sousa ESA; Miyashiro D; Teixeira FME; Custódio RWA; Nakaya HI; Ramos YAL; Sotto MN; Woetmann A; Ødum N; Duarte AJDS; Sanches JA; Sato MN
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902104
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 4 and interferon-gamma expression of the dermal infiltrate in patients with erythroderma and mycosis fungoides. An immuno-histochemical study.
Sigurdsson V; Toonstra J; Bihari IC; Bruijnzeel-Koomen CA; van Vloten WA; Thepen T
J Cutan Pathol; 2000 Oct; 27(9):429-35. PubMed ID: 11028812
[TBL] [Abstract][Full Text] [Related]
3. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
[TBL] [Abstract][Full Text] [Related]
4. Histopathologic studies in Sézary syndrome and erythrodermic mycosis fungoides: a comparison with benign forms of erythroderma.
Sentis HJ; Willemze R; Scheffer E
J Am Acad Dermatol; 1986 Dec; 15(6):1217-26. PubMed ID: 2948972
[TBL] [Abstract][Full Text] [Related]
5. Systemic activation of NLRP3 inflammasome in patients with severe primary Sjögren's syndrome fueled by inflammagenic DNA accumulations.
Vakrakou AG; Boiu S; Ziakas PD; Xingi E; Boleti H; Manoussakis MN
J Autoimmun; 2018 Jul; 91():23-33. PubMed ID: 29551295
[TBL] [Abstract][Full Text] [Related]
6. Sézary syndrome without erythroderma: A review of 16 cases at Mayo Clinic.
Thompson AK; Killian JM; Weaver AL; Pittelkow MR; Davis MD
J Am Acad Dermatol; 2017 Apr; 76(4):683-688. PubMed ID: 28012574
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of NLRP3 inflammasome components and interleukin-18 in patients with bullous pemphigoid.
Fang H; Shao S; Cao T; Lei J; Dang E; Zhang J; Wang G
J Dermatol Sci; 2016 Aug; 83(2):116-23. PubMed ID: 27174093
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of TOX by skin-infiltrating T cells in Sézary syndrome and erythrodermic dermatitis.
Boonk SE; Çetinözman F; Vermeer MH; Jansen PM; Willemze R
J Cutan Pathol; 2015 Sep; 42(9):604-9. PubMed ID: 25777533
[TBL] [Abstract][Full Text] [Related]
9. Sézary syndrome without erythroderma.
Henn A; Michel L; Fite C; Deschamps L; Ortonne N; Ingen-Housz-Oro S; Marinho E; Beylot-Barry M; Bagot M; Laroche L; Crickx B; Maubec E
J Am Acad Dermatol; 2015 Jun; 72(6):1003-9.e1. PubMed ID: 25981000
[TBL] [Abstract][Full Text] [Related]
10. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells.
Vowels BR; Cassin M; Vonderheid EC; Rook AH
J Invest Dermatol; 1992 Jul; 99(1):90-4. PubMed ID: 1607682
[TBL] [Abstract][Full Text] [Related]
11. [A patient with erythroderma and pruritus: Sézary syndrome].
Overweel AFP; Langerak AW; Damman J; de Haas ELM; Weerkamp F; Sandberg Y
Ned Tijdschr Geneeskd; 2022 Feb; 166():. PubMed ID: 35499588
[TBL] [Abstract][Full Text] [Related]
12. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome.
Rook AH; Kubin M; Cassin M; Vonderheid EC; Vowels BR; Wolfe JT; Wolf SF; Singh A; Trinchieri G; Lessin SR
J Immunol; 1995 Feb; 154(3):1491-8. PubMed ID: 7822812
[TBL] [Abstract][Full Text] [Related]
13. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
Eriksen KW; Kaltoft K; Mikkelsen G; Nielsen M; Zhang Q; Geisler C; Nissen MH; Röpke C; Wasik MA; Odum N
Leukemia; 2001 May; 15(5):787-93. PubMed ID: 11368440
[TBL] [Abstract][Full Text] [Related]
14. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
Cirée A; Michel L; Camilleri-Bröet S; Jean Louis F; Oster M; Flageul B; Senet P; Fossiez F; Fridman WH; Bachelez H; Tartour E
Int J Cancer; 2004 Oct; 112(1):113-20. PubMed ID: 15305382
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH
J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
[TBL] [Abstract][Full Text] [Related]
16. A histologic study of lymph nodes from patients with the Sézary syndrome.
Scheffer E; Meijer CJ; van Vloten WA; Willemze R
Cancer; 1986 Jun; 57(12):2375-80. PubMed ID: 2938724
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor agonists partially restore the production of pro-inflammatory cytokines and type I interferon in Sézary syndrome.
Manfrere KC; Torrealba MP; Miyashiro DR; Oliveira LM; de Carvalho GC; Lima JF; Branco AC; Pereira NZ; Pereira J; Sanches JA; Sato MN
Oncotarget; 2016 Nov; 7(46):74592-74601. PubMed ID: 27780938
[TBL] [Abstract][Full Text] [Related]
18. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
[TBL] [Abstract][Full Text] [Related]
19. [The Sézary syndrome].
Ferreira F; Correia TM; Callabro L; Andrade J
Acta Med Port; 1998 Dec; 11(12):1135-9. PubMed ID: 10192992
[TBL] [Abstract][Full Text] [Related]
20. Early clinical manifestations of Sézary syndrome: A multicenter retrospective cohort study.
Mangold AR; Thompson AK; Davis MD; Saulite I; Cozzio A; Guenova E; Hodak E; Amitay-Laish I; Pujol RM; Pittelkow MR; Gniadecki R
J Am Acad Dermatol; 2017 Oct; 77(4):719-727. PubMed ID: 28709694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
